KCA
Search
- Page Path
- HOME > Search
Original Article
- Lung and Thoracic cancer
- Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias
- Ying Yu, Ning Chen, Sizhe Yu, Wanji Shen, Wanchen Zhai, Hui Li, Yun Fan
- Cancer Res Treat. 2024;56(3):751-764. Published online January 2, 2024
- DOI: https://doi.org/10.4143/crt.2023.1118
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to variations in dealing with immortal-time bias (ITB).
Materials and Methods
We retrospectively enrolled 425 advanced NSCLC patients who received anti–PD-(L)1 monotherapy between January 2016 and June 2021, stratifying them into irAE (n=127) and non-irAE (n=298) groups. The primary endpoint was to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Landmark (2-, 3-, 6-, and 9-month) and time-dependent Cox analyses were performed to eliminate ITB.
Results
With a median follow-up of 38.8 months, the occurrence of overall irAEs was significantly associated with superior PFS (11.2 vs. 3.4 months, p < 0.001) and OS (31.4 vs. 14.0 months, p < 0.001), which persisted in landmark and time-dependent Cox analyses. For the main organ-specific irAEs, skin, thyroid, and hepatic irAEs, respectively, showed significantly improved survival compared to the non-irAE group, whereas pneumonitis did not. Single-organ irAEs had the best outcomes compared with multi-organ or no irAE, which also held across subgroups of skin, thyroid, and hepatic irAEs. Moreover, severe grade irAEs and immunotherapy discontinuation had a detrimental effect on survival, systemic steroid therapy showed little effect, while immunotherapy resumption had tolerable safety and a trend of improved survival.
Conclusion
After adequately adjusting ITB, the occurrence of overall irAEs predicts for favorable efficacy of anti–PD-(L)1 monotherapy in NSCLC, with better outcomes observed in patients with skin, thyroid, or hepatic irAEs, particularly those with single-organ involvement. -
Citations
Citations to this article as recorded by
- Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
Yusuke Inoue, Naoki Inui
Internal Medicine.2026; 65(1): 71. CrossRef - Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors
Tianhang Zhang, Xiao Chen, Jianhua Wu, Jiasong Li, Zhukun Qin, Ruijie Cao, Wei Guo, Zhanjun Guo, Haiyan Fan
Frontiers in Immunology.2026;[Epub] CrossRef - Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact
Filip Marković, Mihailo Stjepanović, Milica Kontić
Current Oncology.2026; 33(2): 109. CrossRef - Association of Immune‐Related Adverse Events and the Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer: Adjusting for Immortal Time Bias
Yoshiki Kuwabara, Hiroyuki Ohya, Maiko Osawa, Kota Shiraishi, Itsuka Matsumoto, Shigeru Ishii, Shin Yokosuka, Masatoshi Abe, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Maiko Toda‐Sasaki, Yumiko Kobayashi‐Ogawa, Satoshi Kikuchi, Yusuke Hirata,
Thoracic Cancer.2026;[Epub] CrossRef - Association of SGLT2 inhibitors with hematologic malignancies in type 2 diabetes: a target trial emulation study
Yuan-Tsung Tseng, Chang-Sung Tsai, Mita Restinia, Chih-Wei Tseng, Ting-Yu Chen, Chung-Yi Li
Diabetes Research and Clinical Practice.2026; 236: 113236. CrossRef - Effectiveness of electronic patient-reported outcomes in patients with cancer undergoing immunotherapy: a real-world retrospective study
Hideyuki Katsura, Yukio Suga, Shinji Kimoto, Reiko Ando Makihara, Hiroshi Ota, Hitomi Toi, Naoko Takata, Hiroaki Ikesue
International Journal of Clinical Oncology.2026;[Epub] CrossRef - Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima
Nature Reviews Endocrinology.2025; 21(5): 289. CrossRef - Case Report and Literature Review on Skin Toxicity Induced by PD-1 Inhibitor in a Penile Cancer with Massive Ulceration of Chemoradiotherapy-Resistant and Successful Treatment by Immunotherapy
Yanyan Zhu, Daxia Cai, Jiangle Jiang, Jianfei Tu, Zhifeng Tian, Xiayan Zhang, Songmei Luo, Yonghui Wang
Clinical, Cosmetic and Investigational Dermatology.2025; Volume 18: 699. CrossRef - Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors
Kaori Matsumoto, Tatsuo Kanda, Junichiro Wakatsuki, Young-Jin Kim, Ritsuko Yokouchi, Naho Sato, Yuko Hasegawa, Kenji Amemiya, Yosuke Hirotsu, Sumio Hirose, Yushi Imai, Shinya Takaoka, Hiroyuki Amano, Yukiko Asakawa, Kouwa Nagasaka, Yoshiki Asahina, Yuichi
Hepatology International.2025; 19(5): 1221. CrossRef - The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study
Bicheng Zhang, Yuxiao Song, Qian Min, Weiting Cheng, Jun Wang, Yang Fu, Jiaxin Yin
Frontiers in Immunology.2025;[Epub] CrossRef - Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
Min Xiao, Lan Qian, Qiu Zhao, Jian Ma, Qianxiao Li, Qian Liu, Zhiyan Bi
Oncology Letters.2025; 30(1): 1. CrossRef - Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases
Sida Cheng, Ruijie Zhang, Feng Yang, Jianfeng Li, Huimin Zhao, Lixin Zhou, Geyun Chang, Kunkun Sun, Min Zhang, Xiang Yan, Fan Yang
Lung Cancer.2025; 205: 108592. CrossRef - The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials
Yun Xu, Baoliang Zhong, Chunlin Yu, Qingjian Hou, Wenying Chen, Wen Zheng, Wenxiong Zhang, Tonggang Zhou
Frontiers in Oncology.2025;[Epub] CrossRef - Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy
Mengying Qian, Ping Ma, Yu Zhao, Hao Jiang, LiYang Gao, Gaoyang Lin, Difan Duan, Jinmin Guo
Frontiers in Immunology.2025;[Epub] CrossRef - Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction
Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Koki Otake, Masahiko Ando, Tomoko Handa, Takashi Miyata, Mariko Sugiyama, Takeshi Onoue, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Megumi Inoue, Makoto Ishii, Hiroshi Arima, Shintaro Iw
Frontiers in Endocrinology.2024;[Epub] CrossRef - The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
Tianhang Zhang, Haitao Lv, Jiasong Li, Shasha Zhang, Jingjing Zhang, Siqi Wang, Yingnan Wang, Zhanjun Guo
Frontiers in Immunology.2024;[Epub] CrossRef
- Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
- 8,286 View
- 209 Download
- 17 Web of Science
- 16 Crossref
First
Prev
